In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will MorphoSys Trade Profitability for More Products, More Opportunities, and More Risk?

Executive Summary

Morphosys is a rare biotech company in that it is both an R&D driven enterprise and is profitable at the same time, thanks mostly to a variety of antibody discovery deals it has signed over the years with pharmaceutical partners. As the company brings more product candidates into the clinic will its profitability become a strategic liability, imposing limits on how much it can spend to drive products forward?

You may also be interested in...



MorphoSys Hopes FDA Incentive Programs Can Boost Proprietary Plans

MorphoSys’s ambition to grow a proprietary pipeline got a boost with FDA giving its lead compound MOR208 fast track status for the treatment of relapsed or refractory diffuse large B-cell lymphoma.

MorphoSys: Accelerating The Long Transformation

Flush with funds from new partnering deals and recent capital injections, German biotech MorphoSys plans to boost its already considerable R&D spending to build value in the pipeline while holding on to promising assets longer.

MorphoSys Finds Right Time To Focus On Pipeline With AbD Serotec Sale To Bio-Rad Labs

MorphoSys sells some of its assets in an effort to concentrate on its proprietary therapeutic endeavors – including a mid-stage rheumatoid arthritis drug.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV003227

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel